Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-054580
Filing Date
2021-04-26
Accepted
2021-04-23 18:02:31
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2113795d2_defa14a.htm DEFA14A 22028
2 GRAPHIC image_001.jpg GRAPHIC 560898
3 GRAPHIC image_002.jpg GRAPHIC 241030
  Complete submission text file 0001104659-21-054580.txt   1128223
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33958 | Film No.: 21850871
SIC: 2834 Pharmaceutical Preparations